207 related articles for article (PubMed ID: 31260299)
1. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Yao X; Sun X; Jin S; Yang L; Xu H; Rao Y
J Med Chem; 2019 Jul; 62(14):6561-6574. PubMed ID: 31260299
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
4. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
[TBL] [Abstract][Full Text] [Related]
5. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
[TBL] [Abstract][Full Text] [Related]
7. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Babu Boga S; Alhassan AB; Yu W; Selyutin O; Yu Y; Anand R; Xu J; Kelly J; Duffy JL; Liu S; Yang C; Wu H; Cai J; Bennett C; Maloney KM; Tyagarajan S; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA
Bioorg Med Chem Lett; 2020 Sep; 30(17):127390. PubMed ID: 32738973
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Kawahata W; Asami T; Kiyoi T; Irie T; Taniguchi H; Asamitsu Y; Inoue T; Miyake T; Sawa M
J Med Chem; 2018 Oct; 61(19):8917-8933. PubMed ID: 30216722
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
[TBL] [Abstract][Full Text] [Related]
10. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
[TBL] [Abstract][Full Text] [Related]
11. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
Zhang D; Xu G; Zhao J; Wang Y; Wu X; He X; Li W; Zhang S; Yang S; Ma C; Jiang Y; Ding Q
Eur J Med Chem; 2021 Dec; 225():113724. PubMed ID: 34391034
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Pteridine-7(8
Dou D; Diao Y; Sha W; Su R; Tong L; Li W; Leng L; Xie L; Yu Z; Song H; Shen Z; Zhu L; Zhao Z; Xie H; Chen Z; Li H; Xu Y
J Med Chem; 2022 Feb; 65(3):2694-2709. PubMed ID: 35099969
[TBL] [Abstract][Full Text] [Related]
16. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
17. Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis.
Fang X; Liu C; Zhang K; Yang W; Wu Z; Shen S; Ma Y; Lu X; Chen Y; Lu T; Hu Q; Jiang Y
Eur J Med Chem; 2023 Jan; 246():114940. PubMed ID: 36462441
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors.
Joshi D; Bahekar R; Soman S; Jadav P; Patel D; Goswami A; Pethani J; Kumar J; Patel J; Sundar R; Goswami P; Goshdastidar K; Patel H; Patel A; Bandyopadhyay D; Chattarjee A; Sharma M; Jain M; Desai R
Bioorg Chem; 2023 Jan; 130():106238. PubMed ID: 36403335
[TBL] [Abstract][Full Text] [Related]
20. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Pery N; Rizvi NB; Shafiq MI
J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
